Dec 29, 2008 - Ipsen today announced that the US FDA issued a Complete Response Letter for its Biologics License Application (BLA) for its Botulinum toxin Type A, Dysport. The application, submitted by the Group in late 2007, seeks approval to market Dysport for the treatment of cervical dystonia.
The details can be read here.
No comments:
Post a Comment